TP53 and neoplasm: However, some of the point missense mutations have also been shown to have dominant oncogenic functions (gain-of-function mutations) that can override WT p53 from a remaining WT TP53 allele, via binding to other transcription factors that transactivate genes associated with tumor survival and drug resistance [54] (Figure 1).